Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014863
Filing Date
2024-11-07
Accepted
2024-11-07 16:06:55
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nrbo-20240930x10q.htm   iXBRL 10-Q 1248267
2 EX-31.1 nrbo-20240930xex31d1.htm EX-31.1 38445
3 EX-31.2 nrbo-20240930xex31d2.htm EX-31.2 38439
4 EX-32.1 nrbo-20240930xex32d1.htm EX-32.1 8350
5 EX-32.2 nrbo-20240930xex32d2.htm EX-32.2 8558
6 GRAPHIC nrbo-20240930x10q001.jpg GRAPHIC 10438
  Complete submission text file 0001558370-24-014863.txt   5905878

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrbo-20240930.xsd EX-101.SCH 41079
8 EX-101.CAL nrbo-20240930_cal.xml EX-101.CAL 33465
9 EX-101.DEF nrbo-20240930_def.xml EX-101.DEF 132188
10 EX-101.LAB nrbo-20240930_lab.xml EX-101.LAB 340920
11 EX-101.PRE nrbo-20240930_pre.xml EX-101.PRE 261099
70 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20240930x10q_htm.xml XML 1084857
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 241435590
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)